ENVARSUS
Total Payments
$1.4M
Transactions
1,745
Doctors
852
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $447,824 | 679 | 432 |
| 2023 | $758,028 | 1,046 | 547 |
| 2021 | $60,352 | 1 | 0 |
| 2019 | $109,625 | 16 | 16 |
| 2018 | $3,009 | 3 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 57 | 73.4% |
| Consulting Fee | $142,300 | 51 | 10.3% |
| Space rental or facility fees (teaching hospital only) | $80,550 | 36 | 5.8% |
| Honoraria | $73,655 | 28 | 5.3% |
| Food and Beverage | $49,118 | 1,529 | 3.6% |
| Travel and Lodging | $21,444 | 44 | 1.6% |
Payments by Type
Research
$1.0M
57 transactions
General
$367,067
1,688 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| COGNITIVE OUTCOMES IN STABLE RENAL TRANSPLANT PATIENTS SWITCHED FROMTACROLIMUS TO ENVARSUS XR (OPERATOR) | Veloxis Pharmaceuticals, Inc. | $123,275 | 0 |
| ASSESSMENT OF MEDICATION ADHERENCE AMONG KIDNEY, PANCREAS, AND LIVER TRANSPLANT RECIPIENTS WITH VARYING DEGREES OF SOCIAL RISK, WHO RECEIVED EITHER LCPT OR IR TACROLIMUS | Veloxis Pharmaceuticals, Inc. | $120,293 | 0 |
| VELOXIS DE NOVO KIDNEY TRANSPLANT ECSWD | Veloxis Pharmaceuticals, Inc. | $82,096 | 0 |
| EVALUATION OF EARLY DOSE ESCALATION USING EXTENDED RELEASE TACROLIMUS (ENVARSUS XR) TO REDUCE ACUTE REJECTION AND DONOR SPECIFIC ANTIBODIES IN AFRICAN AMERICAN RENAL TRANSPLANT RECIPIENTS | Veloxis Pharmaceuticals, Inc. | $63,950 | 0 |
| COGNITIVE OUTCOMES IN STABLE RENAL TRANSPLANT PATIENTS SWITCHED FROMTACROLIMUS TO ENVARSUS XR(OPERATOR) | Veloxis Pharmaceuticals, Inc. | $61,637 | 0 |
| CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients | Veloxis Pharmaceuticals, Inc. | $60,352 | 0 |
| A PROSPECTIVE, PILOT TRIAL TO COMPARE THE EFFICACY OF TACROLIMUS EXTENDED-RELEASE (ENVARSUS XR) TO TACROLIMUS IMMEDIATE-RELEASE ON SUPPRESSION OF DONOR-SPECIFIC ANTIBODIES IN HLA SENSITIZED KIDNEY TRANSPLANT RECIPIENTS | Veloxis Pharmaceuticals, Inc. | $53,908 | 0 |
| ENVARSUS XR COMPARED TO IMMEDIATE RELEASE TACROLIMUS (SIMPLE) | Veloxis Pharmaceuticals, Inc. | $51,000 | 0 |
| RETROSPECTIVE EVALUATION OF DOSING WEIGHT OF TACROLIMUS EXTENDED RELEASE (ENVARSUS XR) IN OBESE KIDNEY TRANSPLANT RECIPIENTS IN THE DE NOVO SETTING | Veloxis Pharmaceuticals, Inc. | $49,776 | 0 |
| A PROSPECTIVE, RANDOMIZED, SINGLE-CENTER, PILOT STUDY OF ENVARSUS XR TO EXAMINE SAFETY, MEDICATION ADHERENCE, AND PATIENT REPORTED OUTCOMES IN ADOLESCENT RENAL TRANSPLANT RECIPIENTS | Veloxis Pharmaceuticals, Inc. | $47,651 | 0 |
| THE EFFECT OF CONVERSION TO ONCE-DAILY ENVARSUS ON THE NEUROLOGIC TOXICITY BURDEN IN LIVER TRANSPLANT RECIPIENTS | Veloxis Pharmaceuticals, Inc. | $40,033 | 0 |
| BIDIRECTIONAL EFFECT OF ENVARSUS AND THE GUT MICROBIOME IN LIVER TRANSPLANT RECIPIENTS | Veloxis Pharmaceuticals, Inc. | $39,557 | 0 |
| IMPACT OF ENVARSUS XR ON KIDNEY BIOPSY SUBCLINICAL REJECTION AND BLOOD IMMUNOLOGIC PROFILE | Veloxis Pharmaceuticals, Inc. | $34,011 | 0 |
| A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, SINGLE-CENTER STUDY OF PULSE WAVE VELOCITY EVALUATOIN, TACROLIMUS TIME IN THERAPEUTIC RANGE, AND CO-EFFICIENT OF TACROLIMUS VARIATION OF AFRICAN AMERICAN KIDNEY TRANSPLANT RECIPIENTS RECEIVING IMMEDIATE RELEASE TACROLIMUS CAPSULES (IR-TAC) OR EXTENDED RELEASE TACROLIMUS TABLETS (LCPT) | Veloxis Pharmaceuticals, Inc. | $31,975 | 0 |
| TACROLIMUS VARIABILITY AND MEDICATION ADHERENCE BEFORE AND AFTER CONVERSION TO LCP-TACROLIMUS (ENVARSUS XR) ANTIREJECTION THERAPY FROM IMMEDIATE-RELEASE TACROLIMUS IN PEDIATRIC SOLID ORGAN TRANSPLANT RECIPIENTS | Veloxis Pharmaceuticals, Inc. | $25,798 | 0 |
| EARLY USE OF LONG-ACTING TACROLIMUS IN LUNG TRANSPLANT RECIPIENTS | Veloxis Pharmaceuticals, Inc. | $25,519 | 0 |
| ASSESSMENT OF RENAL TUBULAR INJURY AND TRANSPLANT OUTCOMES IN CARDIAC RECIPIENTS CONVERTING FROM IMMEDIATE RELEASE TACROLIMUS TO EXTENDED RELEASE TACROLIMUS | Veloxis Pharmaceuticals, Inc. | $22,223 | 0 |
| ASSESSMENT OF THE INTESTINAL CYP3A CONTRIBUTION TO DRUG INTERACTIONS WITH ENVARSUS XR USING GRAPEFRUIT JUICE | Veloxis Pharmaceuticals, Inc. | $21,745 | 0 |
| A 12 MONTH SINGLE-CENTER, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY TO EVALUATE ENVARSUS XL STEROID-FREE RABBIT ANTI-THYMOCYTE GLOBULIN INDUCTION ON RENAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING LIVER TRANSPLANTATION | Veloxis Pharmaceuticals, Inc. | $21,105 | 0 |
| A PILOT STUDY TO EVALUATE IMPACT ON NEUROLOGICAL SIDE EFFECTS (COGNITION, MEMORY, AND TREMOR) IN ELDERLY (AGE>65) PATIENTS | Veloxis Pharmaceuticals, Inc. | $16,538 | 0 |
Top Doctors Receiving Payments for ENVARSUS — Page 10
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Nephrology | Scottsdale, AZ | $81.34 | 2 |
| , MD | Nephrology | Albuquerque, NM | $79.59 | 4 |
| , MD | Nephrology | Tucson, AZ | $78.94 | 2 |
| , MD | Nephrology | Tucson, AZ | $78.94 | 2 |
| , MD | Transplant Surgery | Loma Linda, CA | $78.19 | 3 |
| , FNP | Family | Augusta, GA | $77.00 | 3 |
| , M.D | Hepatology | Shreveport, LA | $76.84 | 3 |
| , PA-C | Physician Assistant | Shreveport, LA | $76.84 | 3 |
| , APRN, AGACNP-BC | Acute Care | San Antonio, TX | $74.64 | 3 |
| , M.D | Transplant Surgery | San Diego, CA | $74.56 | 1 |
| , APRN, FNP-C | Nurse Practitioner | Dallas, TX | $74.47 | 3 |
| Eliana Villado | Nurse Practitioner | Dallas, TX | $74.47 | 3 |
| , M.D | Internal Medicine | Loma Linda, CA | $73.84 | 3 |
| Steven Elzein | Student in an Organized Health Care Education/Training Program | Houston, TX | $72.98 | 1 |
| , MD | Nephrology | Louisville, KY | $72.81 | 3 |
| , APRN | Family | Louisville, KY | $72.81 | 3 |
| , MD | Urology | Oklahoma City, OK | $72.52 | 3 |
| , M.D | Nephrology | Indianapolis, IN | $72.51 | 3 |
| , M.D | Nephrology | Tulsa, OK | $71.87 | 2 |
| , MD | Hospitalist | Southfield, MI | $71.80 | 3 |
| , MD | Nephrology | Port Charlotte, FL | $71.80 | 3 |
| , MD | Surgery | New York, NY | $70.88 | 1 |
| , FNP-C | Family | Evans, GA | $70.57 | 3 |
| , FNP | Primary Care | Augusta, GA | $70.57 | 3 |
| , MSN, APRN, AGACNP-BC | Acute Care | Galveston, TX | $70.29 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 852
- Transactions 1,745
About ENVARSUS
ENVARSUS is a drug associated with $1.4M in payments to 852 healthcare providers, recorded across 1,745 transactions in the CMS Open Payments database. The primary manufacturer is Veloxis Pharmaceuticals, Inc..
Payment data is available from 2018 to 2024. In 2024, $447,824 was paid across 679 transactions to 432 doctors.
The most common payment nature for ENVARSUS is "Unspecified" ($1.0M, 73.4% of total).
ENVARSUS is associated with 20 research studies, including "COGNITIVE OUTCOMES IN STABLE RENAL TRANSPLANT PATIENTS SWITCHED FROMTACROLIMUS TO ENVARSUS XR (OPERATOR)" ($123,275).